| Today’s Big NewsNov 21, 2024 |
| By James Waldron Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space recently when it decided to acquire Kate Therapeutics, according to the Big Pharma’s CEO. |
|
|
|
By Gabrielle Masson In a few weeks, Howard Chang, M.D., Ph.D., will join Amgen, filling the roles both of senior vice president of research and chief scientific officer. |
By Darren Incorvaia Enveda, a company using AI to boost nature-based drug discovery, is envisioning clinical success with a $130 million series C fundraising round. The round was led by Kinnevik and FPV with other new and existing investors such as Dimension Capital, Lux Capital and The Nature Conservancy also taking part. |
Sponsored by Adaptive Biotechnologies Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance. |
|
Explore the latest additions to the GS®️ expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During this webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems. 
|
|
By James Waldron Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data showing it wasn’t getting good value from its medicines, CEO Vas Narasimhan, M.D., told investors. |
Sponsored by Dell Technologies Head of Life Sciences Strategy Alex Long shares key insights and advice for IT professionals working to enable healthcare’s technology transformation. |
By Gabrielle Masson VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments. |
By Zoey Becker The Johns Hopkins surgeon was an outspoken critic of vaccine mandates during the COVID pandemic, favoring natural and herd immunity instead. Bloomberg and Reuters, citing sources, reported on the potential selection. |
By Darren Incorvaia Viking Therapeutics has unveiled the final results of its phase 2b VOYAGE trial of oral small molecule VK2809 in metabolic dysfunction associated steatohepatitis (MASH). At the 52-week mark, the drug reduced liver fat content by an average of 37% to 55% compared to baseline, with all treatment arms showing statistically significant improvements compared to placebo. |
By James Waldron Kyowa Kirin is fronting $330 million and pledging up to $1.1 billion in milestones to split the U.S. profits of Kura's oral leukemia treatment as well as to secure the commercialization rights for the rest of the world. |
By Darren Incorvaia Novartis is looking to edit the genomes of patient T cells without the immune cells ever needing to leave the body. To develop this next generation of in vivo T cell therapy, the Big Pharma has bought into Minnesota-based Vyriad’s suite of lentivirus vectors. |
By Angus Liu A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star ADC Enhertu. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
|
The future of gene therapy is here, but with it comes manufacturing constraints, supply chain issues, and regulatory questions. Join us on November 20 for the Fierce Cell and Gene Virtual Event. Register Now! 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
